Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis

References

• Falzon D, Raviglione M. TB control: achievements, obstacles and the role of vaccines. In: Norazmi MN, Acosta A, Sarmiento ME, eds. The Art &Science of tuberculosis vaccine development. 2nd ed. Malaysia. Oxford University Press. p.13-29. ISBN 978 983 47 0355 4 (http://tbvaccines.usm.my/finlay/) (2014)
   Google Scholar
• Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368(8):745-55; PMID:23425167; http://dx.doi.org/10.1056/NEJMra1200894
   PubMed Web of Science ®Google Scholar
• Zumla A, George A, Sharma V, Herbert N, Baroness Masham of Ilton. WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 2013;382(9907):1765-7; PMID:24269294; http://dx.doi.org/10.1016/S0140-6736(13)62078-4
   PubMedGoogle Scholar
• Kaufmann SHE, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AL, Maeurer M. Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review. Lancet Respir Med 2014;2(4):301-20; PMID:24717627; http://dx.doi.org/10.1016/S2213-2600(14)70033-5
   PubMedGoogle Scholar
• McShane H: Tuberculosis vaccines: beyond bacilli Calmette-Guérin. Philos Trans R Soc Lond B Biol Sci 2011;366:2782-9; PMID:21893541; http://dx.doi.org/10.1098/rstb.2011.0097
   PubMed Web of Science ®Google Scholar
• Smith I: Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 2003;16(3):463-96; PMID:12857778; http://dx.doi.org/10.1128/CMR.16.3.463-496.2003
   PubMed Web of Science ®Google Scholar
• Morandi M, Sali M, Manganelli R, Delogu G. Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis. J Infect Dev Ctries 2013;7(3):169-81; PMID:23492994; http://dx.doi.org/10.3855/jidc.3114
   PubMedGoogle Scholar
• Lopez-Marin LM. Nonprotein structures from mycobacteria: emerging actors for tuberculosis control. Clin Dev Immunol 2012;2012:917860; PMID:22611423; http://dx.doi.org/10.1155/2012/917860
   PubMedGoogle Scholar
• Kasmar AG, Layre E, Moody B. Lipid adjuvants and antigens embedded in the mycobacterial cell envelope. In: Norazmi MN, Acosta A, Sarmiento ME, eds. The Art &Science of tuberculosis vaccine development. 2nd ed. Malaysia. Oxford University Press. p. 123-149. ISBN 978 983 47 0355 4 (http://tbvaccines.usm.my/finlay/) (2014)
   Google Scholar
• Pérez JL, Acevedo R, Callicó A, Fernández Y, Cedré B, Año G, Gonzalez L, Falero G, Talavera A, Perez O, et al: A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine 2009;27(2):205-12; http://dx.doi.org/10.1016/j.vaccine.2008.10.052
   PubMed Web of Science ®Google Scholar
• Sotolongo F, Campa C, Casanueva V, Fajardo EM, Cuevas IE, González N: Cuban Meningococcal BC Vaccine: experiences and contributions from 20 years of application. MEDICC Rev 2008;9(1):16-22; PMID:21483377
   PubMedGoogle Scholar
• Pérez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D, Zayas C, Acevedo R, Gonzales D, Lopez JA, et al: Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 2004;82(6):603-10; http://dx.doi.org/10.1111/j.1440-1711.2004.01293.x
   PubMed Web of Science ®Google Scholar
• Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, Pryor M, Duthoy S, Grondin S, Lacroix C, Monsempe C, et al: The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci U S A 2003;100(13):7877-82; PMID:12788972; http://dx.doi.org/10.1073/pnas.1130426100
   PubMedGoogle Scholar
• Zhang W, Zhang Y, Zheng H, Pan Y, Liu H, Du P, Wan L, Liu J, Zhu B, Zhao G, Chen C, Wan K. Genome sequencing and analysis of BCG vaccine strains. PLoS One 2013;8(8):e71243; PMID:23977002; http://dx.doi.org/10.1371/journal.pone.0071243
   PubMed Web of Science ®Google Scholar
• Gomes LH, Otto TD, Vasconcellos EA, Ferrão PM, Maia RM, Moreira AS, Ferreira MA, Castello-Branco LR, Degrave WM, Mendonça-Lima L. Genome sequence of Mycobacterium bovis BCG Moreau, the Brazilian vaccine strain against tuberculosis. J Bacteriol 2011;193(19):5600-1; PMID:21914899; http://dx.doi.org/10.1128/JB.05827-11
   PubMed Web of Science ®Google Scholar
• Reyes F, Tirado Y, Puig A, Borrero R, Reyes G, Fernández S, Pérez J L, Kadir R, Zayas C, Norazmi MN, et al: Immunogenicity and cross-reactivity against Mycobacterium tuberculosis of proteoliposomes derived from Mycobacterium bovis BCG. BMC Immunol 2013;14(Suppl 1):S7; PMID:23458692
   PubMedGoogle Scholar
• Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R, Fernandez S, Reyes G, Alvarez N, Garcia MA, et al: Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine 2011; 29(37):6236-41; PMID:21736914; http://dx.doi.org/10.1016/j.vaccine.2011.06.077
   PubMed Web of Science ®Google Scholar
• Cervantes-Villagrana A, Hernández-Pando R, Biragyn A, Castañeda-Delgado J, Bodgain M, Martínez-Fierro M, Sada E, Trujillo V, Enciso-Moreno A, Rivas-Santiago B. Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine 2013; 31: 676-84; PMID:23196205; http://dx.doi.org/10.1016/j.vaccine.2012.11.042
   PubMed Web of Science ®Google Scholar
• Hernández Pando R, Aguilar D, Orozco H, Serrano A, Ahlem C, Trauger R, Schramm B, Reading C, Frincke J, Rook G: 16alpha-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis. J Infect Dis 2005;191(2):299-306; http://dx.doi.org/10.1086/426453
   PubMed Web of Science ®Google Scholar
• Canadian Council On Animal Care: Guide to the care and use of experimental animals. Ottawa, Ont; 1984; 1(2).
   Google Scholar
• Jeon BY, Kim HJ, Kim SC, Jo EK, Park JK, Paik TH, Kim SJ, Cho SN. Protection of mice against Mycobacterium tuberculosis infection by immunization with aqueous fraction of Triton X-100-soluble cell wall proteins. Scand J Immunol 2008;67(1):18-23; PMID:18021187
   PubMed Web of Science ®Google Scholar
• Doherty TM, Andersen P: Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 2005;18(4):687-702; PMID:16223953; http://dx.doi.org/10.1128/CMR.18.4.687-702.2005
   PubMedGoogle Scholar
• Young DB, Perkins MD, Duncan K, Barry CE 3rd. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 2008;118(4):1255-65; PMID:18382738; http://dx.doi.org/10.1172/JCI34614
   PubMedGoogle Scholar
• Dye C. Tuberculosis 2000-2010: control, but not elimination. Int J Tuberc Lung Dis 2000;4(12 Suppl 2):S146-52; PMID:11144545
   PubMed Web of Science ®Google Scholar
• al-Kassimi FA, al-Hajjaj MS, al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? Am J Respir Crit Care Med 1995;152(5 Pt 1):1575-8; PMID:7582297; http://dx.doi.org/10.1164/ajrccm.152.5.7582297
   PubMedGoogle Scholar
• Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995;96(1 Pt 1):29-35; PMID:7596718
   PubMed Web of Science ®Google Scholar
• Lanckriet C, Lévy-Bruhl D, Bingono E, Siopathis RM, Guérin N. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. Int J Epidemiol 1995;24(5):1042-9; PMID:8557438; http://dx.doi.org/10.1093/ije/24.5.1042
   PubMedGoogle Scholar
• Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271(9):698-702; PMID:8309034; http://dx.doi.org/10.1001/jama.1994.03510330076038
   PubMed Web of Science ®Google Scholar
• Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346(8986):1339-45; PMID:7475776; http://dx.doi.org/10.1016/S0140-6736(95)92348-9
   PubMed Web of Science ®Google Scholar
• Brewer TF. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000;31(Suppl 3):S64-7; PMID:11010824; http://dx.doi.org/10.1086/314072
   PubMed Web of Science ®Google Scholar
• Dietrich J, Doherty TM. Subunit Vaccines against infection with MTB; preclinical and clinical considerations. In: Norazmi MN, Acosta A, Sarmiento ME, eds. The Art &Science of tuberculosis vaccine development. 2nd ed. Malaysia. Oxford University Press. p. 693-737. ISBN 978 983 47 0355 4 (http://tbvaccines.usm.my/finlay/) (2014)
   Google Scholar
• Brennan MJ, Sweeney AR, Woolley J, Clagett B, Barker LF. New TB vaccines. What is the pipeline? In: Norazmi MN, Acosta A, Sarmiento ME, eds. The Art &Science of tuberculosis vaccine development. 2nd ed. Malaysia. Oxford University Press. p. 949-981. ISBN 978 983 47 0355 4 (http://tbvaccines.usm.my/finlay/) (2014)
   Google Scholar
• Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S: Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect Immun 2005;73(8): 4676-83; PMID:16040980; http://dx.doi.org/10.1128/IAI.73.8.4676-4683.2005
   PubMedGoogle Scholar
• Romano M, D'Souza S, Adnet PY, Laali R, Jurion F, Palflied K, Huygen K: Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006;24(16): 3353-64; PMID:16488518; http://dx.doi.org/10.1016/j.vaccine.2005.12.066
   PubMedGoogle Scholar
• Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z: Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006;74(8):4634-43; PMID:16861651; http://dx.doi.org/10.1128/IAI.00517-06
   PubMed Web of Science ®Google Scholar
• Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H: Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2007;2(10): e1052; PMID:17957238; http://dx.doi.org/10.1371/journal.pone.0001052
   PubMedGoogle Scholar
• Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekon WA, et al; MVA85A020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381(9871):1021-8; PMID:23391465; http://dx.doi.org/10.1016/S0140-6736(13)60177-4
   PubMed Web of Science ®Google Scholar
• Morandi M, Sali M, Manganelli R, Delogu G. Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis. J Infect Dev Ctries. 2013;7(3):169-81; PMID:23492994; http://dx.doi.org/10.3855/jidc.3114
   PubMedGoogle Scholar
• Lopez-Marin LM. Non protein structures from mycobacteria: emerging actors for tuberculosis control. Clin Dev Immunol. 2012;2012:917860; PMID:22611423; http://dx.doi.org/10.1155/2012/917860
   PubMedGoogle Scholar
• Dascher C, Hiromatsu K, Xiong X, Morehouse C, Watts G, Llu G, McMurray D, LeClair K, Porcelli S, Brenner M: Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int. Immunol. 2003;15(8):915-25; PMID:12882829; http://dx.doi.org/10.1093/intimm/dxg091
   PubMed Web of Science ®Google Scholar
• Singh AP, Khuller GK. Liposomes as a carrier for mannophosphoinositide antigens of mycobacteria. Indian J Biochem Biophys. 1993;30(3):160-5; PMID:8406546
   PubMed Web of Science ®Google Scholar
• Singh AP, Khuller GK. Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A. FEMS Immunol Med Microbiol. 1994;8(2):119-26; PMID:8173551; http://dx.doi.org/10.1111/j.1574-695X.1994.tb00433.x
   PubMedGoogle Scholar
• García MA, Borrero R, Lanio ME, Tirado Y, Alvarez N, Puig A, Aguilar A, Canet L, Mata Espinoza D, Barrios Payán J, et al. Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis. Biomed Res Int. 2014; 2014:273129.
   Google Scholar
• WHO. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec. 2007;82(21):193-6; PMID:17526121
   PubMedGoogle Scholar